Magenta Therapeutics CSO Dr. Lisa Olson departs effective May 15, 2023 amid proposed merger with Dianthus
Dianthus Therapeutics, Inc. /DE/
Dr. Lisa Olson, Head of Research and CSO, left Magenta on May 15, 2023 due to completion of certain asset sales and announced proposed merger with Dianthus.
Magenta entered into a consulting agreement with Dr. Olson for work on an as-requested basis at an hourly rate.
Dr. Olson is eligible for severance benefits under her amended employment agreement, subject to execution of a separation agreement.
The departure is part of restructuring related to the proposed merger with Dianthus Therapeutics.
Effective May 15, 2023, Dr. Lisa Olson, Head of Research and Chief Scientific Officer of Magenta Therapeutics, Inc. (the “Company” or “Magenta”), has left the Company due to the completion of the sale of certain of Magenta’s assets and its announced proposed merger with Dianthus Therapeutics, Inc. (“Dianthus”).
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Dr. Lisa Olson departed as Head of Research and Chief Scientific Officer at Dianthus Therapeutics, Inc. /DE/.
Action
left
Role
Head of Research and Chief Scientific Officer
Exact text from the filing
Effective May 15, 2023, Dr. Lisa Olson, Head of Research and Chief Scientific Officer of Magenta Therapeutics, Inc. (the “Company” or “Magenta”), has left the Company due to the completion of the sale of certain of Magenta’s assets and its announced proposed merger with Dianthus Therapeutics, Inc. (“Dianthus”).
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.